A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Inclusion Criteria

• •Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
• •Subject with established diagnosis of metastatic castration-resistant prostate carcinoma.
• •Subject is being newly initiated on Xtandi treatment (Enzalutamide).
• •Subject has an estimated life expectancy of ≥ 6 months.
• •Subject agrees not to participate in another interventional study while participating in the present study.